Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease

Core Insights - The FDA has cleared Serina Therapeutics' Investigational New Drug (IND) application for SER-252, an investigational therapy for advanced Parkinson's disease, marking a significant milestone for the company [1][2][3] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications, utilizing its proprietary POZ Platform for drug optimization [4] - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [4] POZ Platform Technology - The POZ technology is based on a synthetic, water-soluble polymer called poly(2-oxazoline), designed to enhance drug loading control and precision in drug release rates via subcutaneous injection [5] - This technology aims to improve the efficacy and safety profiles of various drug modalities, including small molecules and RNA-based therapeutics [5] - Serina plans to advance additional applications of the POZ platform through partnerships, including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery formulations [6] SER-252 Development - SER-252 is an investigational apomorphine therapy developed using the POZ platform, intended to provide continuous dopaminergic stimulation (CDS) to reduce levodopa-related motor complications in Parkinson's disease [7] - Preclinical studies suggest that SER-252 may offer CDS without causing skin reactions, addressing a significant unmet medical need in the treatment of advanced Parkinson's disease [7]